Fenwick & West represented OrsoBio in the transaction. OrsoBio,Inc. a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, announced raising its $67 million Series...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Liquid Death in the transaction. Liquid Death, the healthy beverage platform and one of fastest growing non-alcoholic brands, announced it closed $67 million...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented Samsara BioCapital in the transaction. Alumis Inc. announced an upsized $259M Series C financing round co-led by existing investor, Foresite Capital, and new...
You must be a Standard 1 Year member to access this content.
Fenwick & West represented OrsoBio in the transaction. OrsoBio, Inc. announced its $60 million Series A financing, bringing the total capital raised by the Company to $97 million....
You must be a Standard 1 Year member to access this content.
Fenwick & West represented A-Alpha Bio in the transaction. A-Alpha Bio announced its $22.4 million Series A2 financing. The round was led by previous investor Perceptive Xontogeny...
You must be a Standard 1 Year member to access this content.
Fenwick represented Remitly on the deal. Remitly (NASDAQ: RELY), a global digital financial services provider for immigrants and their families, signed the agreement to acquire Rewire, an...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Remitly on the deal. Davis Polk advised several underwriters on the deal. Remitly Global, Inc. (Nasdaq: RELY), a mobile-first provider of remittances...
You must be a Standard 1 Year member to access this content.
Fenwick & West advised Vanqua Bio on the deal. Vanqua Bio, a biopharmaceutical company dedicated to discovering and developing next-generation medicines for neurodegenerative diseases, announced its $85...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal while Fenwick & West represented Lycia Therapeutics. Lycia Therapeutics, Inc., a leader in extracellular protein...
You must be a Standard 1 Year member to access this content.
